Atlas Trials

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Clinical trial NCT06752408 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06752408
Sponsor
Peking Union Medical College Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2024-12-17
Primary completion
2027-01-16
Enrollment
316

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.